Recent therapeutic advances in metastatic renal cell carcinoma (RCC) have included agents targeted against vascular endothelial growth factor (VEGF).
A pioneering implantable artificial kidney developed jointly by teams of researchers at Cleveland Clinic, the University of California at San Francisco, and the University of Michigan in Ann Arbor is on track to meet project milestones in a pilot and feasibility study funded by the NIH.
The provision of in-hospital dialysis services over the next decade will necessitate a rethinking of the unit infrastructure.
Partial nephrectomy has been the procedure of choice for patients with poor renal function, tumors in solitary kidneys or bilateral renal tumors.
Considering the advancement in the diagnosis and treatment of glomerular disease, we formed a Glomerulonephritis Board (GN Board) at Cleveland Clinic that brings together key medical specialists.
The electronic medical record (EMR) has enabled creation of a CKD registry, a database that contains demographic information, clinical parameters, and outcome measurements of more than 41,000 CKD patients who have received medical care within the Cleveland Clinic Health System since January 2005.
There is sufficient evidence to demonstrate that lowering BP to less than 140/90 mm Hg offers cardiovascular and renal protection.
Prostate magnetic resonance (MR) provides high-resolution images of the prostate; seminal vesicles; and nearby pelvic organs and structures, including the bladder and rectum.
Data from 1,000 former kidney donors suggest that normal values of glomerular filtration rate decline with age.
Jihad Kaouk, MD, Director of the Center for Laparoscopic and Robotic Surgery, and his team performed the world's first completely transvaginal nephrectomy on March 13, 2009.
Last year, our lab team received a grant from the Flight Attendants Medical Research Institute (FAMRI). FAMRI was created from a settlement with tobacco companies over flight attendant exposure to secondhand smoke in their work.
A urethral sling placed via a transobturator approach has recently emerged as a treatment option for men with mild-to-moderate postprostatectomy incontinence.
About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4.0 ng/mL did not always assist in accurately categorizing a man's risk for prostate cancer, we began to eliminate this—or any—artificial cutoff defining a "normal" PSA value.
Eric A. Klein, MD, a thought leader in the biology and management of prostate cancer, has been appointed chairman of the Glickman Urological & Kidney Institute.
The number of candidates on the list for kidney transplantation due to end-stage renal disease after a prior nonrenal transplant, particularly liver transplant, is growing significantly.
Researchers are examining the role of iron-regulatory proteins in patients with CKD-related anemia
It improves range of motion and motor precision in ergonomically challenging surgical cases
The medication is being tested as adjuvant therapy in patients with locally advanced urothelial cancer.
Prevalence data suggest that during their lifetimes, up to half of U.S. women experience some level of female pelvic floor disorders (FPFD). However, despite the prevalence of FPFD, little is known about their pathophysiology.
We recently reported our initial experience with single-port transvesical enucleation of the prostate (STEP) performed through a solitary suprapubic incision via a single-access port inserted directly into the bladder in three patients with symptomatic BPH.
Evidence from our latest study has demonstrated a cause-and-effect relationship between cell-phone usage and poor semen quality, recognized as a common cause for male factor infertility.
Although the traditional approach to prostate cancer has been to target the entire gland, Cleveland Clinic has offered focal cryotherapy on a very limited basis since 2005 for men with low-risk disease who understand the implications of all treatment options.
Development of postoperative acute renal failure (ARF) increases the mortality after cardiac surgery to 50%. Previous attempts at therapeutic interventions have failed, and the survival rate associated with ARF remains dismal.
A multidisciplinary consortium of 28 surgeons from the United States and around the world convened for a one-day closed-door brainstorming meeting at Cleveland Clinic on July 7. The consortium's goal was to establish an approach to advance responsibly the rapidly growing field of single-portal laparoscopic surgery.
The recently developed single-port, multichannel access approach to urologic surgery may allow many common laparoscopic and robotic procedures to be performed entirely through the patient's umbilicus, enabling essentially scarless abdominal surgery. To date, Cleveland Clinic has performed 115 single-port laparoscopic procedures for various indications.
Most patients with end-stage renal disease (ESRD) depend on hemodialysis and suffer excessive mortality and morbidity. Kidney failure is becoming an epidemic in the United States, fueled by diabetes, obesity and, paradoxically, improved cardiac care.
A year and a half ago, Cleveland Clinic's Glickman Urological Institute and Nephrology Department joined to form the Glickman Urological & Kidney Institute. Merging urologists, nephrologists, kidney and pancreas transplant surgeons, hypertension specialists, dialysis physicians, and scientists into one group was part of an institution-wide movement at Cleveland Clinic that organized clinical areas around organ and disease systems rather than individual specialties.
Surgeons at the Cleveland Clinic's Glickman Urological and Kidney Institute completed their 1,000th laparoscopic partial nephrectomy (LPN) on Aug.7, making their experience with the procedure the most extensive in the world.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)